U.S. Fertility Market (By Offering: Assisted Reproductive Technology, Fertility Drugs, Others; By End User: Fertility Clinics, Hospitals, Clinical Research Institutes) - Regional Outlook and Forecast 2024 to 2033
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: U.S. Fertility Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. U.S. Fertility Market Revenue and Volume, by Offering, 2024-2033
8.1.1. Assisted Reproductive Technology
8.1.1.1. Market Revenue and Volume Forecast (2021-2033)
8.1.2. Fertility Drugs
8.1.2.1. Market Revenue and Volume Forecast (2021-2033)
8.1.3. Others
8.1.3.1. Market Revenue and Volume Forecast (2021-2033)
9.1. U.S. Fertility Market Revenue and Volume, by End User, 2024-2033
9.1.1. Fertility Clinics
9.1.1.1. Market Revenue and Volume Forecast (2021-2033)
9.1.2. Hospitals
9.1.2.1. Market Revenue and Volume Forecast (2021-2033)
9.1.3. Clinical Research Institutes
9.1.3.1. Market Revenue and Volume Forecast (2021-2033)
10.1. U.S.
10.1.1. Market Revenue and Volume Forecast, by Offering (2021-2033)
10.1.2. Market Revenue and Volume Forecast, by End User (2021-2033)
11.1. Boston IVF Fertility Clinic
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. INVO Bioscience
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. San Diego Fertility Center
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Celmatix
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. FUJIFILM IRVINE SCIENTIFIC
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Carolinas Fertility Institute
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Progyny Inc.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Cook Medical
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client